TFF Pharmaceuticals, Inc., an Austin, Texas-based early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions, closed a $14m Series A funding.
National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc. (NASDAQ: NHLD), acted as sole placement agent for the offering. The Liquid Venture Partners group at National Securities Corporation was responsible for sourcing and executing the $14 million offering.
The company will use the funds to develop its pipeline of transformative dry powder drugs for pulmonary diseases and conditions such as lung transplant, severe asthma, COPD, and pulmonary infections.
Led by Robert Mills, CEO, TFF Pharmaceuticals is an early-stage biopharmaceutical company focused on the development and commercialization of new inhalation products for the treatment of chronic respiratory diseases and lung conditions. TFF leverages Thin Film Freezing (TFF) proprietary platform, which, in early testing, improved the solubility of drugs that have poor water solubility.
The platform does not require a proprietary device, excipient or delivery molecule to obtain deep lung delivery of small molecules, biologics, or uniform combo drugs of small molecules and/or biologics. The technology, with a combination of 30 patents and applications, is licensed exclusively from the University of Texas at Austin.